MDxHealth SA
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MDXH | PEB.NZ | PROGEN.ST | IMDX | GDR.L | MYGN | |
|---|---|---|---|---|---|---|
| Market cap | 14.92M | 310.47M | 16.10M | 86.72M | 15.88M | 575.81M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.4 | -20.8 | -1.0 | -3.3 | 0.0 | -10.2 |
| Price/book | -0.3 | 25.0 | 0.9 | -4.1 | — | 1.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −96.65% | +24.32% | −80.24% | −58.86% | −1.91% | −4.90% |
| Today | −1.26% | +8.70% | −1.90% | −3.28% | +1.42% | −0.33% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All MDXH news ›Reviewing Geron (NASDAQ:GERN) and MDxHealth (NASDAQ:MDXH)
Posted by Mitch Edgeman on Nov 3rd, 2026 Geron (NASDAQ:GERN – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses…
Financial Review: MDxHealth (NASDAQ:MDXH) and ImmunityBio (NASDAQ:IBRX)
Posted by Michael Walen on Nov 2nd, 2026 ImmunityBio (NASDAQ:IBRX – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on…
MDxHealth’s (MDXH) Neutral Rating Reaffirmed at BTIG Research
MDxHealth (NASDAQ:MDXH – Get Free Report)‘s stock had its “neutral” rating reiterated by investment analysts at BTIG Research in a note issued to investors on Monday, Benzinga reports. Check Out Our Latest Report on MDXH MDxHealth is a…
MDxHealth (NASDAQ:MDXH) Stock Rating Cut to “Hold” at Lake Street Capital
Posted by Defense World Staff on Oct 17th, 2026 Lake Street Capital lowered shares of MDxHealth (NASDAQ:MDXH – Free Report) from a buy rating to a hold rating in a report published on Friday morning, MarketBeat reports. They currently have…
MDxHealth Suspends Full-Year Guidance on Flat Q3 Revenues
MDxHealth Reports Flat Preliminary Q3 Revenues, Suspends Full-Year Guidance GenomeWeb MDxHealth Reports Flat Preliminary Q3 Revenues, Suspends Full-Year Guidance
MDxHealth: Bleichroeder reports 32.04% stake
MDxHealth SA (MDXH) is a precision diagnostics company focused on molecular tests for prostate cancer and other urologic diseases, using genomic and epigenetic technologies. - [SCHEDULE 13D/A] MDxHealth SA Amended Major Shareholder Report…
MDxHealth suspends $110–115M revenue guidance for 2026
Tissue-based tests fell 11%; liquid-based tests totaled 11,792 versus 4,600, with the earlier period including Select mdx and Exo mdx. MDxHealth SA expects to report preliminary, unaudited third-quarter 2026 revenue from continuing…
MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance
GameSquare Announces The "Grand Theft Auto" Effect ASHFORD HOSPITALITY TRUST ANNOUNCES $17 MILLION ADVISORY FEE WAIVER, SHARE PURCHASE COMMITMENT FROM ASHFORD INC. AND TERMINATION OF ATM PROGRAM Cipher Digital Announces Date of Third…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net3
- stocktitan.net3
- genomeweb.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.